<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Health Serv Res</journal-id><journal-id journal-id-type="iso-abbrev">BMC Health Serv Res</journal-id><journal-title-group><journal-title>BMC Health Services Research</journal-title></journal-title-group><issn pub-type="epub">1472-6963</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11681667</article-id><article-id pub-id-type="publisher-id">12152</article-id><article-id pub-id-type="doi">10.1186/s12913-024-12152-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Economic evaluation of tenofovir disoproxil fumarate prophylaxis to prevent mother-to-child transmission of Hepatitis B virus infection: evidence from a lower-middle income country</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nguyen</surname><given-names>Ha T.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chaikledkaew</surname><given-names>Usa</given-names></name><address><email>usa.chi@mahidol.ac.th</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hoang</surname><given-names>Minh V.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Tran</surname><given-names>Viet Q.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Thavorncharoensap</surname><given-names>Montarat</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Praditsitthikorn</surname><given-names>Naiyana</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Tran</surname><given-names>Quang D.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Thakkinstian</surname><given-names>Ammarin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01znkr924</institution-id><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, </institution></institution-wrap>Bangkok, 10400 Thailand </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00waaqh38</institution-id><institution-id institution-id-type="GRID">grid.444808.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2037 434X</institution-id><institution>University of Health Sciences, Vietnam National University Ho Chi Minh City, </institution></institution-wrap>Binh Duong City, 820000 Vietnam </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01znkr924</institution-id><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, </institution></institution-wrap>Bangkok, 10400 Thailand </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01mxx0e62</institution-id><institution-id institution-id-type="GRID">grid.448980.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 7651</institution-id><institution>Hanoi University of Public Health, </institution></institution-wrap>Hanoi, 100000 Vietnam </aff><aff id="Aff5"><label>5</label>Military Hospital 175, Ho Chi Minh City, Vietnam </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03rn0z073</institution-id><institution-id institution-id-type="GRID">grid.415836.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0576 2573</institution-id><institution>Division of Innovation and Research, Department of Disease Control, Ministry of Public Health, </institution></institution-wrap>Nonthaburi, 11000 Thailand </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00ntrnw83</institution-id><institution-id institution-id-type="GRID">grid.512137.3</institution-id><institution>Communicable Disease Control Division, General Department of Preventive Medicine, Vietnam Ministry of Health, </institution></institution-wrap>Hanoi, 100000 Vietnam </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01znkr924</institution-id><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Department of Clinical Epidemiology and Biostatistics, </institution><institution>Faculty of Medicine Ramathibodi Hospital, Mahidol University, </institution></institution-wrap>Bangkok, 10400 Thailand </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>24</volume><elocation-id>1658</elocation-id><history><date date-type="received"><day>22</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">No cost-effectiveness information of preventive strategies for mother-to-child transmission (MTCT) of hepatitis B virus (HBV) has existed for policy decision making. This study aimed to compare the cost-effectiveness of alternative strategies to prevent MTCT of HBV in Vietnam. Cost-utility analysis using a hybrid decision-tree and Markov model were performed from healthcare system and societal perspectives. Preventive strategies included HBV universal vaccination (S1), hepatitis B immunoglobulin (HBIG) for infants of mothers with HBeAg(&#x02009;+) (S2), HBIG for infants of mothers with HBsAg(&#x02009;+) (S3), tenofovir disoproxil fumarate (TDF) for mothers with high viral load (S4) and mothers with HBeAg(&#x02009;+) (S5), and the current practice (S6) with HBV vaccine in all infants and TDF for high viral load mothers. The current practice was dominant to all preventive strategies with interventions in only infants for both perspectives. In contrast, the strategies S4 and S5 were dominant to the current practice with incremental net monetary benefit varying from $33.94 to $70.64 under a healthcare system perspective and from $44.22 to $93.71 under a societal perspective. Addition of HBIG in infants born to mothers infected HBV and tenofovir prophylaxis for mothers with positive HBeAg was the most cost-effective strategy to prevent vertical transmission of HBV in Vietnam.
</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12913-024-12152-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Economic evaluation</kwd><kwd>Mother-to-child transmission</kwd><kwd>Hepatitis B</kwd><kwd>Preventive strategies</kwd><kwd>Vietnam</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>OPP1087363</award-id><principal-award-recipient><name><surname>Chaikledkaew</surname><given-names>Usa</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Mahidol University</institution></funding-source></award-group><open-access><p>Open access funding provided by Mahidol University</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par27">Hepatitis B virus (HBV) is a major public health problem, with approximately 296 million with chronic hepatitis B (CHB) and 820,000 deaths in 2019 worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. In high prevalence regions, mother-to-child transmission (MTCT) accounted for the major path of HBV transmission [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], in which rate of CHB is noticeably very high among infants infected at birth or during the first year of life as compared to older population [<xref ref-type="bibr" rid="CR4">4</xref>]. In 2016, elimination of viral hepatitis was set as the global public health threat, in which one important goal was to reduce the prevalence of hepatitis B surface antigen (HBsAg) among children under 5&#x000a0;years to 0.1% [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par28">The efficacy of HBV vaccine, hepatitis B immunoglobulin (HBIG) in infants, and antiviral-agents of tenofovir disoproxil fumarate (TDF) for MTCT prevention has been proven in previous meta-analyses and network meta-analyses of randomized clinical trails (RCTs) [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>], and these have been recommended in clinical practice guidelines [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. Although the TDF prophylaxis is recommended in mother with high viral load (VL) in most guidelines [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>], this may not be accessible in resource constrained settings due to its high cost and high-technology requirements of HBV DNA quantitative test. To overcome this barrier, since 2020 the World Health Organization (WHO) [<xref ref-type="bibr" rid="CR13">13</xref>] has recommended the usage of HBeAg test as a proxy for high VL to improve accessibility and reduce inequities across population.</p><p id="Par29">Vietnam was one of countries with high prevalence of HBV, approximately 10.5% in adult population and 10.8% among pregnant women [<xref ref-type="bibr" rid="CR14">14</xref>]. Since 2018, the Vietnam Ministry of Health has issued the action plan to eliminate MTCT of HBV by 2030. The combination of HBIG and HBV vaccine birth dose (BD) in infants of HBsAg(&#x02009;+) mothers has been recommended [<xref ref-type="bibr" rid="CR15">15</xref>], and TDF prophylaxis should be provided for pregnant women with high VL. Currently, HBV vaccine has been provided in the National Expand Program on Immunization (NEPI), and TDF has been included in the health-coverage scheme. However, HBIG has not yet been covered and patients must bear the cost of $72 per dose by out-of-pocket [<xref ref-type="bibr" rid="CR16">16</xref>]. Consequently, only less than 7% of patients could get access to HBIG [<xref ref-type="bibr" rid="CR17">17</xref>]. Furthermore, HBV DNA quantitative test is available and reimbursed only in provincial or higher level of hospitals, while HBeAg test can be reimbursed in lower level of hospitals. Therefore, the usage of HBeAg test as a proxy of high VL, recommended by the WHO [<xref ref-type="bibr" rid="CR13">13</xref>], is feasible to scale up prevention.</p><p id="Par30">Evidence on cost-effectiveness is important to support the making of decision on which HBV MTCT preventive strategy should be implemented in Vietnam. Nevertheless, such evidence has not yet been found. According to our systematic review [<xref ref-type="bibr" rid="CR18">18</xref>], most cost-effectiveness of HBV MTCT preventive strategies were performed in high-income countries (HIC) and only one study in the border of an upper-middle-income country (UMIC) and lower-middle-income country (LMIC), where medical services were provided in refugee camps. Therefore, we aimed to compare the cost-effectiveness of six HBV MTCT preventive strategies in order to provide evidence to support for policy decision making in Vietnam and other similar settings.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Target population</title><p id="Par31">All pregnant women who were screened for HBsAg as per the WHO guideline [<xref ref-type="bibr" rid="CR19">19</xref>]. This cost-utility analysis model allowed us to construct the whole birth cohort of newborns in 2022 and their mothers in Vietnam.</p></sec><sec id="Sec4"><title>Intervention and comparators</title><p id="Par32">According to current guidelines [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>] and WHO&#x02019;s recommendations updated in March 2024 [<xref ref-type="bibr" rid="CR20">20</xref>], six preventive strategies (S1-S6) were designed to provide preventive strategies in infants (i.e., HBV vaccination and HBIG) and in mothers (i.e., TDF administration). Table <xref rid="Tab1" ref-type="table">1</xref> presents details of each preventive strategy.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Description of preventive strategies to prevent HBV mother-to-child transmission</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Strategy number</th><th align="left" rowspan="2">Strategies name</th><th align="left" rowspan="2">HBV biomarker test</th><th align="left" colspan="2">Intervention in infants</th><th align="left">TDF prophylaxis in mothers</th></tr><tr><th align="left">
<bold>Vaccine</bold>
</th><th align="left">
<bold>HBIG</bold>
</th><th align="left"/></tr></thead><tbody><tr><td align="left">S1</td><td align="left">Universal vaccination</td><td align="left">(-)</td><td align="left">(&#x02009;+)</td><td align="left">(-)</td><td align="left">(-)</td></tr><tr><td align="left">S2</td><td align="left">
<bold>HBIG for infants of mothers with HBeAg(&#x02009;+)</bold>
</td><td align="left"><p>(&#x02009;+)</p><p>HBsAg test</p><p>HBeAg test</p></td><td align="left">(&#x02009;+)</td><td align="left">(&#x02009;+)</td><td align="left">(-)</td></tr><tr><td align="left">S3</td><td align="left">
<bold>HBIG for infants of mothers with HBsAg(&#x02009;+)</bold>
</td><td align="left"><p>(&#x02009;+)</p><p>HBsAg test</p></td><td align="left">(&#x02009;+)</td><td align="left">(&#x02009;+)</td><td align="left">(-)</td></tr><tr><td align="left">S4</td><td align="left">TDF for mothers with high viral load</td><td align="left"><p>(&#x02009;+)</p><p>HBsAg test</p><p>HBV DNA</p></td><td align="left">(&#x02009;+)</td><td align="left">(&#x02009;+)</td><td align="left">(&#x02009;+)</td></tr><tr><td align="left">S5</td><td align="left">TDF for mothers with HBeAg(&#x02009;+)</td><td align="left"><p>(&#x02009;+)</p><p>HBsAg test</p><p>HBeAg test</p></td><td align="left">(&#x02009;+)</td><td align="left">(&#x02009;+)</td><td align="left">(&#x02009;+)</td></tr><tr><td align="left">S6</td><td align="left">Current practice</td><td align="left"><p>(&#x02009;+)</p><p>HBsAg test</p><p>HBV DNA</p></td><td align="left">(&#x02009;+)</td><td align="left">(-)</td><td align="left">(&#x02009;+)</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec5"><title>Model structure</title><p id="Par33">A hybrid decision tree and Markov model were constructed to compare costs and health outcomes of six preventive strategies considering both societal and healthcare perspectives. Average total costs and health outcomes were estimated during patients&#x02019; lifetime period with a cycle length of one year using a half-cycle correction. Local clinical experts were consulted to validate the model structure to assure that disease progression pathway was appropriate and also reflected local context.</p><p id="Par34">All pregnant women entered the decision tree model under six preventive strategies (Figure S<xref rid="MOESM1" ref-type="media">1</xref>). At the age of one year, the infants without HBV infection entered Markov M1, which consisted of two health states, i.e., living without CHB and death, see Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. Infants with positive HBV entered Markov M2, which illustrated lifetime progression of CHB patients due to vertical transmission consisting four non-cirrhotic CHB states and three CHB consequence states (i.e., compensated cirrhosis (CC), decompensated cirrhosis (DCC) and hepatocellular carcinoma (HCC)). In addition, the Markov M2 also included two other states, including resolution (HBsAg seroclearance) and death. Model was built and run using the Microsoft Office Excel 2016.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Markov model structure. HBV: Hepatitis B virus; CHB: Chronic hepatitis B; HCC: Hepatocellular carcinoma</p></caption><graphic xlink:href="12913_2024_12152_Fig1_HTML" id="MO1"/></fig></p><sec id="Sec6"><title>Model assumptions</title><p id="Par35">Infants vaccinated with HBV vaccine BD were assumed to complete three doses as per the NEPI, and vaccination would result in lifelong protection. This model ignored horizontal transmission, therefore newborns of HBsAg(-) mothers were assumed not to be infected. In addition, patients in the CC, DCC and HCC states were assumed to die due to liver related causes, while others had the same mortality rate as general population.</p></sec><sec id="Sec7"><title>Model parameters</title><sec id="Sec8"><title>Screening effectiveness and efficacy of interventions</title><p id="Par36">The performance of HBsAg rapid diagnostic test (RDT) was obtained from a systematic review and meta-analysis which was performed to support for the WHO guideline on HBV testing [<xref ref-type="bibr" rid="CR21">21</xref>]. Meanwhile, coverage of other HBV biomarker tests was obtained from the Department of Maternal Health and Children in Vietnam and expert consultations.</p><p id="Par37">Preventive efficacy of different interventions measured by the percentage of HBV MTCT at age of 6&#x02013;12&#x000a0;months were systematically synthesized by the team [<xref ref-type="bibr" rid="CR6">6</xref>]. Due to the lack of data from RCTs, the efficacy of HBV vaccine in infants, HBV vaccine plus HBIG in infants of mothers with high and low VLs were assumed to be similar to those in infants of HBeAg(&#x02009;+) and HBeAg(-) mothers, respectively as per the WHO&#x02019;s recommendations on the usage of HBeAg as a proxy of high VL.</p></sec><sec id="Sec9"><title>Transition probabilities</title><p id="Par38">Transition probabilities among different states in the Markov model were obtained from published literatures and consultation with local experts. The rate of all-cause mortality was obtained from the life-table of Vietnamese population via the WHO website [<xref ref-type="bibr" rid="CR22">22</xref>]. Epidemiological parameters were retrieved from previous surveys in Vietnam [<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec10"><title>Costs</title><p id="Par39">Costs of HBIG and TDF were estimated from the bidding results of whole country in Vietnam in 2021. Meanwhile, costs of HBV biomarker screening tests were obtained from the National List of Medical Service in Vietnam in 2021. Direct medical cost (DMC) of non-cirrhotic CHB was estimated based on a retrospective primary data collection in a tertiary military hospital in Vietnam in 2020. Cost-at-charge approach was applied to convert all charges to cost values. Other cost components were borrowed from previous economic evaluations (EEs) [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] in Vietnam. All costs were converted to the USD 2022 using Vietnam consumer price index [<xref ref-type="bibr" rid="CR26">26</xref>] and exchange rate of $1.00&#x02009;=&#x02009;23,132 Vietnamese Dong.</p></sec><sec id="Sec11"><title>Health outcomes</title><p id="Par40">The 5-level EQ-5D (EQ-5D-5L) utility values of health states were borrowed from an observational study on 319 non-cirrhotic CHB patients [<xref ref-type="bibr" rid="CR27">27</xref>] in China and the study [<xref ref-type="bibr" rid="CR24">24</xref>] which collected primary data on CC, DCC and HCC patients in Vietnam. Both costs and outcomes were discounted at a rate of 3% based on Ministry of Health&#x02019;s recommendation on EE reporting in Vietnam. Details on input parameters&#x02019; values were presented in the Table S<xref rid="MOESM1" ref-type="media">1</xref>.</p></sec></sec></sec><sec id="Sec12"><title>Result presentation</title><p id="Par41">The incremental net monetary benefits (INMB) of alternative strategies S1-S5 compared to the current practice S6 were estimated given the willingness-to-pay (WTP) threshold of Vietnam as follows: INMB&#x02009;=&#x02009;Incremental QALYs x WTP &#x02013; Incremental costs. In this study, we used the WTP of one GDP per capita ($3,855) because the interested intervention strategies were for preventions, in which the WTP was usually lower than that of treatment interventions [<xref ref-type="bibr" rid="CR28">28</xref>].</p><sec id="Sec13"><title>Uncertainty analysis</title><p id="Par42">One-way sensitivity analysis (OWSA) was performed to investigate the most influential parameters on the INMB. Dispersion of key parameters were estimated based on 95% confidence interval (CI). If the 95% CI was not available, a standard error (SE) of 20% of base-case value was applied. In addition, probabilistic sensitivity analysis (PSA) with 10,000 Monte Carlo simulations was also performed. Furthermore, due to the lack of robust data on the coverage of screening tests and prophylactic interventions, three different scenarios corresponding to targeted coverages varied from 50 to 95% for three consecutive durations from 2018 to 2030 according to the action plan issued by Vietnam Ministry of Health were analyzed [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec></sec><sec id="Sec14"><title>Results</title><sec id="Sec15"><title>Costs and health outcomes</title><p id="Par43">From healthcare system perspective, average costs of three strategies in infants only (i.e., S1, S2 and S3) varied from $47.40 to $48.85 per infant, which were higher than those of preventive strategies in both mothers and infants (S4-S6) accounting from $36.02 to $40.92, see Figure S<xref rid="MOESM2" ref-type="media">2</xref>A. In addition, the two strategies with the addition of HBIG in infants of HBsAg(&#x02009;+) mothers and TDF prophylaxis in pregnant women (i.e., S4 and S5) incurred lower cost than the current practice S6 (accounted $40.92), which provided TDF prophylaxis in only mothers with high VL without HBIG in infants. Noticeably, CHB treatment cost accounted for the major proportion of total costs in all preventive strategies (Figure S<xref rid="MOESM2" ref-type="media">2</xref>A). Similar trend was observed from the societal perspective. However, the addition of direct non-medical cost and time costs increased the average cost more than three times relative to healthcare system perspective costs (Figure S<xref rid="MOESM2" ref-type="media">2</xref>B). Regarding the rate of CHB among 1-year-old children, the current practice resulted in a rate of 0.97%, as compared to 0.86% and 0.76% in strategy S4 (HBIG in infant of HBsAg(&#x02009;+) mothers plus TDF in only high VL mothers) and S5 (HBIG in infant of HBsAg(&#x02009;+) mothers plus TDF in only HBeAg(&#x02009;+) mothers), respectively. In contrast, all three S1, S2, and S3 in only infants led to higher rates of CHB, varying from 1.09% to 1.27%. The similar trend was observed in all scenarios with different coverages of prophylactic interventions (Figure S3).</p></sec><sec id="Sec16"><title>Cost-effectiveness analysis</title><p id="Par44">For the healthcare perspective, all three S1, S2, S3 in only infants were dominated whereas the S4 and S5 were contrastingly dominant comparing with the current practice of S6. At the WTP of one GDP per capita, the INMB of S4 and S5 were $33.94 and $70.64, respectively, while the INMBs of S1, S2 and S3 varied from $&#x02212;100.81 to $ &#x02212;43.01. Similar trend was also found for the societal perspective (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Estimation of ICER and INMB comparing different strategies with the current practice</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Prophylactic strategy</th><th align="left">LY</th><th align="left">Inc. LY</th><th align="left">QALY</th><th align="left">Inc. QALY</th><th align="left">Cost ($)</th><th align="left">Inc. Cost<break/>($)</th><th align="left">ICER</th><th align="left">INMB ($)</th></tr></thead><tbody><tr><td align="left" colspan="9">
<bold>From healthcare system perspective</bold>
</td></tr><tr><td align="left">&#x02003;S1: Universal Vaccination</td><td align="left">29.0606</td><td align="left"> &#x02212;0.0097
</td><td align="left">28.9997</td><td align="left"> &#x02212;0.0241
</td><td align="left">48.85</td><td align="left">7.93</td><td align="left">Dominated</td><td align="left"> &#x02212;100.81
</td></tr><tr><td align="left">&#x02003;S2: HBIG for infants of mothers with HBeAg(&#x02009;+)</td><td align="left">29.0644</td><td align="left">&#x02212;0.0059
</td><td align="left">29.0092</td><td align="left">&#x02212;0.0146
</td><td align="left">47.40</td><td align="left">6.48</td><td align="left">Dominated</td><td align="left">&#x02212;62.67
</td></tr><tr><td align="left">&#x02003;S3: HBIG for infants of mothers with HBsAg(&#x02009;+)</td><td align="left">29.0665</td><td align="left">&#x02212;0.0038
</td><td align="left">29.0143</td><td align="left">&#x02212;0.0095
</td><td align="left">47.46</td><td align="left">6.54</td><td align="left">Dominated</td><td align="left">&#x02212;43.01
</td></tr><tr><td align="left">&#x02003;S4: TDF for mothers with high viral load</td><td align="left">29.0738</td><td align="left">0.0035</td><td align="left">29.0326</td><td align="left">0.0088</td><td align="left">40.83</td><td align="left">&#x02212;0.09
</td><td align="left">Dominant</td><td align="left">33.94</td></tr><tr><td align="left">&#x02003;S5: TDF for mothers with HBeAg(&#x02009;+)</td><td align="left">29.0771</td><td align="left">0.0069</td><td align="left">29.0408</td><td align="left">0.0171</td><td align="left">36.02</td><td align="left">&#x02212;4.90
</td><td align="left">Dominant</td><td align="left">70.64</td></tr><tr><td align="left">&#x02003;S6: Current practice</td><td align="left">29.0703</td><td align="left">Reference</td><td align="left">29.0238</td><td align="left">Reference</td><td align="left">40.92</td><td align="left">Reference</td><td align="left">Reference</td><td align="left">Reference</td></tr><tr><td align="left" colspan="9">
<bold>From societal perspective</bold>
</td></tr><tr><td align="left">&#x02003;S1: Universal Vaccination</td><td align="left">29.0606</td><td align="left">&#x02212;0.0097
</td><td align="left">28.9997</td><td align="left">&#x02212;0.0241
</td><td align="left">168.20</td><td align="left">31.76</td><td align="left">Dominated</td><td align="left">&#x02212;124.65
</td></tr><tr><td align="left">&#x02003;S2: HBIG for infants of mothers with HBeAg(&#x02009;+)</td><td align="left">29.0644</td><td align="left">&#x02212;0.0059
</td><td align="left">29.0092</td><td align="left">&#x02212;0.0146
</td><td align="left">156.03</td><td align="left">19.59</td><td align="left">Dominated</td><td align="left">&#x02212;75.79
</td></tr><tr><td align="left">&#x02003;S3: HBIG for infants of mothers with HBsAg(&#x02009;+)</td><td align="left">29.0665</td><td align="left">&#x02212;0.0038
</td><td align="left">29.0143</td><td align="left">&#x02212;0.0095
</td><td align="left">149.67</td><td align="left">13.22</td><td align="left">Dominated</td><td align="left">&#x02212;49.70
</td></tr><tr><td align="left">&#x02003;S4: TDF for mothers with high viral load</td><td align="left">29.0738</td><td align="left">0.0035</td><td align="left">29.0326</td><td align="left">0.0088</td><td align="left">126.07</td><td align="left">&#x02212;10.38
</td><td align="left">Dominant</td><td align="left">44.22</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec17"><title>Parameter uncertainty analysis</title><p id="Par45">Tornado diagrams (Figure S4, Figure S5) indicated that the base-case results were reconfirmed in almost all parameter variations for both perspectives. The S4 and S5 were more cost-effective than S6 when all parameters were varied, except for the efficacy of vaccine plus HBIG compared with vaccine only in infants of HBeAg(-) mothers.</p><p id="Par46">Results from 10,000 simulations confirmed the robustness of the base-case analyses for both perspectives (Table S<xref rid="MOESM2" ref-type="media">2</xref>). The S5 had the highest probability of being the most cost-effective, approximately of 80% (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Noticeably, the cost-effectiveness acceptability curve showed that if the S5 was excluded due to the lack of official recommendation on the TDF prophylaxis in HBeAg(&#x02009;+) mothers in Vietnam, the S4 had the highest probability of being the most cost-effective from both perspectives (Figure S6).
<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Cost-effectiveness acceptability curve by preventive strategies</p></caption><graphic xlink:href="12913_2024_12152_Fig2_HTML" id="MO2"/></fig></p></sec></sec><sec id="Sec18"><title>Scenario analysis</title><p id="Par47">The increase in the coverage of screening tests (i.e., HBsAg, HBeAg, HBV DNA) and HBV vaccine decreased the CHB rate among 1-year infants. It should be noted that in the most optimistic scenario with 95% of pregnant women screened for HBsAg, HBeAg or HBV DNA, and 90% of infants received HBV vaccine, strategies S4 and S5 led to lowest CHB rate of 0.3% among 1-year infants. However, this remains above the Ministry of Health and WHO target, which aims for a CHB rate of 0.1% among infants up to 5&#x000a0;years of age (Figure S3).</p><p id="Par48">As compared to the current practice (S6), the preventive strategies in infants only (i.e., S1, S2, and S3) were not cost-effective, whereas the addition of HBIG in infants with or without the expansion of TDF prophylaxis in mothers with HBeAg(&#x02009;+) was cost-effective from both perspectives in all three scenarios (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, Table S3). The increase of coverage of screening tests, HBV vaccine and TDF prophylaxis increased the benefit of the current practice over strategies with interventions in infants only, but also reduced the benefit of strategies S4 and S5 over the current practice.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Results from scenario analyses based on healthcare system perspective</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Compared strategies</th><th align="left">Inc. QALY</th><th align="left">Inc. Cost ($)</th><th align="left">INMB ($)</th></tr></thead><tbody><tr><td align="left" colspan="4">
<bold>Base-case analysis</bold>
</td></tr><tr><td align="left">&#x02003;S1 vs S6</td><td align="left">&#x02212;0.0241
</td><td align="left">7.9297</td><td align="left">&#x02212;100.8149
</td></tr><tr><td align="left">&#x02003;S2 vs S6</td><td align="left">&#x02212;0.0146
</td><td align="left">6.4762</td><td align="left">&#x02212;62.6727
</td></tr><tr><td align="left">&#x02003;S3 vs S6</td><td align="left">&#x02212;0.0095
</td><td align="left">6.5359</td><td align="left">&#x02212;43.0071
</td></tr><tr><td align="left">&#x02003;S4 vs S6</td><td align="left">0.0088</td><td align="left">&#x02212;0.0893
</td><td align="left">33.9386</td></tr><tr><td align="left">&#x02003;S5 vs S6</td><td align="left">0.0171</td><td align="left">&#x02212;4.8993
</td><td align="left">70.6413</td></tr><tr><td align="left" colspan="4">
<bold>Scenario 1 (50%&#x02212;70%&#x02212;50%&#x02212;80%)*</bold>
</td></tr><tr><td align="left">&#x02003;S1 vs S6</td><td align="left">&#x02212;0.0188
</td><td align="left">6.1868</td><td align="left">&#x02212;78.7696
</td></tr><tr><td align="left">&#x02003;S2 vs S6</td><td align="left">&#x02212;0.0114
</td><td align="left">5.0248</td><td align="left">&#x02212;48.9784
</td></tr><tr><td align="left">&#x02003;S3 vs S6</td><td align="left">&#x02212;0.0074
</td><td align="left">5.0765</td><td align="left">&#x02212;33.6379
</td></tr><tr><td align="left">&#x02003;S4 vs S6</td><td align="left">0.0066</td><td align="left">0.0221</td><td align="left">25.5538</td></tr><tr><td align="left">&#x02003;S5 vs S6</td><td align="left">0.0121</td><td align="left">&#x02212;3.3302
</td><td align="left">50.0071</td></tr><tr><td align="left" colspan="4">
<bold>Scenario 2 (70%&#x02212;90%&#x02212;70%&#x02212;85%)*</bold>
</td></tr><tr><td align="left">&#x02003;S1 vs S6</td><td align="left">&#x02212;0.0339
</td><td align="left">11.3866</td><td align="left">&#x02212;142.0725
</td></tr><tr><td align="left">&#x02003;S2 vs S6</td><td align="left">&#x02212;0.0197
</td><td align="left">8.5258</td><td align="left">&#x02212;84.4584
</td></tr><tr><td align="left">&#x02003;S3 vs S6</td><td align="left">&#x02212;0.0169
</td><td align="left">9.6313</td><td align="left">&#x02212;74.8353
</td></tr><tr><td align="left">&#x02003;S4 vs S6</td><td align="left">0.0070</td><td align="left">1.3521</td><td align="left">25.4777</td></tr><tr><td align="left">&#x02003;S5 vs S6</td><td align="left">0.0135</td><td align="left">&#x02212;3.4056
</td><td align="left">55.4746</td></tr><tr><td align="left" colspan="4">
<bold>Scenario 3 (95%&#x02212;95%&#x02212;95%&#x02212;90%)*</bold>
</td></tr><tr><td align="left">&#x02003;S1 vs S6</td><td align="left">&#x02212;0.0569
</td><td align="left">19.1916</td><td align="left">&#x02212;238.5717
</td></tr><tr><td align="left">&#x02003;S2 vs S6</td><td align="left">&#x02212;0.0354
</td><td align="left">14.5463</td><td align="left">&#x02212;150.8761
</td></tr><tr><td align="left">&#x02003;S3 vs S6</td><td align="left">&#x02212;0.0325
</td><td align="left">16.5366</td><td align="left">&#x02212;141.8209
</td></tr><tr><td align="left">&#x02003;S4 vs S6</td><td align="left">0.0047</td><td align="left">4.2853</td><td align="left">14.0172</td></tr><tr><td align="left">&#x02003;S5 vs S6</td><td align="left">0.0043</td><td align="left">0.8623</td><td align="left">15.8426</td></tr></tbody></table><table-wrap-foot><p>
<sup><italic>*</italic></sup>Coverage of HBsAg, HBeAg, HBV DNA and HBV vaccine birth dose, respectively
</p><p>S1- Universal vaccination; S2-HBIG for infants of mothers with HBeAg(&#x02009;+); S3-HBIG for infants of mothers with HBsAg(&#x02009;+); S4-TDF for mothers with high viral load; S5-TDF for mothers with HBeAg(&#x02009;+); S6-Current practice; Inc.: Incremental; INMB: Incremental net monetary benefit; QALY: Quality-adjusted life year</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec19"><title>Discussion</title><p id="Par49">The base-case analysis indicated that maternal TDF prophylaxis either in high VL (S4) or HBeAg(&#x02009;+) (S5) mothers plus HBIG in infants of HBsAg(&#x02009;+) mothers was more effective but less costly than the current practice. Similar to previous EEs from the UMIC and HIC [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>], our study indicated that from the point of view of an LMIC, although the cost of HBV DNA quantitative test was still high, with the low cost of generic TDF and the significant cost&#x000a0;savings from successful prevention of CHB in newborns, the addition of maternal TDF prophylaxis were still more effective and less costly than interventions in infants only.</p><p id="Par50">Our study indicated that as compared to the maternal TDF prophylaxis plus HBV vaccine in infants, the addition of HBIG in infants of HBsAg(&#x02009;+) mothers was cost-effective, which was different from the findings by Bierhoff M. et al. [<xref ref-type="bibr" rid="CR30">30</xref>]. The authors applied the decision tree model which estimated only screening and preventive cost but not CHB treatment cost [<xref ref-type="bibr" rid="CR30">30</xref>]. It should be noted that from our findings, treatment cost of CHB accounted for major proportion of total lifetime costs. Without considerations of CHB treatment cost, Bierhoff et al. would lead to underestimate the benefit of addition of HBIG. For mothers with HBeAg(-) status, the risk of MTCT of HBV is minimal, especially when universal infant vaccination programs are implemented. The 2020 WHO guidelines emphasize that vaccination alone is sufficient to effectively manage MTCT risks in these cases, without requiring the administration of HBIG [<xref ref-type="bibr" rid="CR13">13</xref>]. Therefore, HBIG is not considered beneficial for infants born to HBeAg(-) mothers. Additionally, universal vaccination also addresses horizontal transmission risks, further reducing the need for additional interventions like HBIG in these scenarios.</p><p id="Par51">As proven in our study, the addition of HBIG in infants was dominant to the current practice from both healthcare and societal perspectives. However, HBIG has not yet been included in the benefit package in Vietnam. Recent updates in the 2024 WHO guidelines have revised the role of HBIG in preventing MTCT of hepatitis B [<xref ref-type="bibr" rid="CR20">20</xref>]. While the 2020 WHO guidelines [<xref ref-type="bibr" rid="CR13">13</xref>] recommended HBIG where available, particularly in combination with maternal TDF prophylaxis and universal infant vaccination, the 2024 guidelines no longer recommend the routine use of HBIG, especially in LMIC [<xref ref-type="bibr" rid="CR20">20</xref>]. HBIG is now primarily suggested in high-resource settings for infants born to HBsAg-positive mothers with high viral loads. This change reflected the limited data supporting the additional benefits of HBIG when used alongside TDF and universal vaccination. Supporting this, a study conducted in the Democratic Republic of the Congo involving nine women found high protective efficacy of maternal TDF combined with infant hepatitis B vaccination, even without HBIG administration [<xref ref-type="bibr" rid="CR35">35</xref>]. This evidence suggests that maternal TDF prophylaxis alone may be sufficient for effective prevention in many settings, though further large-scale studies are needed to confirm these findings. Consistent with these guidelines, our study demonstrates that incorporating HBIG for infants born to HBsAg-positive mothers, alongside expanding TDF prophylaxis to HBeAg-positive mothers, remains highly cost-effective or even dominant compared to current practices. Similar to previous EEs [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], our study indicated that the HBeAg test, used as a proxy of high VL was dominant to HBV DNA quantitative test due to the HBeAg test&#x02019;s broader coverage and lower cost. These findings align with WHO recommendations, which suggest the use of the HBeAg test, especially in regions where HBV DNA quantitative tests are not available. Our study could provide additional evidence on cost-effectiveness to support this recommendation.</p><p id="Par52">To achieve the goal of HBV elimination, one important strategy is to reduce the prevalence of HBsAg(&#x02009;+) in children under 5&#x000a0;years to 0.1% or less [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. However, our study indicated that among 1-year-old children, the incidence of CHB in the current practice was 0.97% and reduced to 0.76% in strategy S5. At the most promising scenario, i.e., 95% of pregnant women were screened for HBsAg, HBeAg or HBV DNA, and 90% of infants received vaccine, incidence of CHB in strategies S4 and S5 reduced to 0.3% among one-year-old infants, which were still higher than the WHO&#x02019;s target of 0.1% for children up to five years. Our results indicated that focusing on vertical transmission was very important, however, this seemed to be not enough to eliminate HBV in Vietnam. Other strategies to screen for HBsAg in general population and provide appropriate interventions need to be taken into account. To comprehensively estimate the benefit of alternative prevention strategies, future studies could consider both vertical and horizontal transmission as well as estimate the benefit from maternal side.</p><p id="Par53">Additionally, the findings highlight the necessity of enhancing the quality and accessibility of universal immunization and screening programs. This could enable earlier identification of high-risk pregnancies and optimize the timing and effectiveness of immunization for infants. To achieve this, increased investment from the Vietnamese government is crucial, particularly in health infrastructure, healthcare worker training, and community outreach efforts. These improvements would ensure more comprehensive and timely screening and vaccination coverage. Furthermore, the WHO Triple Elimination Initiative seeks to eradicate MTCT of human immunodeficiency viruses (HIV), syphilis, and hepatitis B simultaneously [<xref ref-type="bibr" rid="CR38">38</xref>]. The use of a multiplex test, which integrates screening efforts for these infections, could yield cost savings by combining tests and lead to improved health outcomes for both mothers and infants [<xref ref-type="bibr" rid="CR38">38</xref>]. The WHO Triple Elimination Initiative emphasizes the importance of strategic integration in screening practices, which should be a focal point for Vietnamese policymakers when planning future health programs.</p><p id="Par54">As for our knowledge, our study is the first EE comparing long-term outcomes and costs that was performed in an LMIC with high prevalence of HBV taking into account the WHO recent recommendation on the usage of HBeAg test as a proxy of high VL. Our study could provide the evidence to support the considerations of the most cost-effective alternatives to prevent MTCT of HBV &#x02013; an important task toward HBV elimination in Vietnam or other countries with similar contexts. A hybrid model was used to estimate both short-term and long-term costs and health outcomes of six preventive strategies, which was suitable for a life-long disease, especially when serious consequences tended to occur at the older age. Clinical experts were involved in model structure adjustment and assumptions to ensure that patients pathway reflected the local context.</p><p id="Par55">Nevertheless, limitations in the study should be addressed. First, the model ignored horizontal transmission and assumed the lifelong protection of 4-dose schedule of vaccine. It should be noted that WHO did not recommend booster vaccination for people who did complete three doses of HBV vaccination due to the prolonged protection [<xref ref-type="bibr" rid="CR1">1</xref>]. Therefore, horizontal transmission mostly happened to infants who were not vaccinated. In this study, we applied the same coverage of HBV vaccine in all six compared strategies, therefore the impact of horizontal transmission on all strategies was similar and the ignorance of this route of transmission seemed to not significantly impact the main results. Second, due to the lack of data in Vietnam, some parameters were obtained from literatures in other countries. However, several approaches were applied to overcome this limitation, including the prioritization of parameters from high level of evidence, consultation with local experts and performance of uncertainty analyses.</p><p id="Par56">Our results suggested that the current practice was dominant to all strategies with interventions in infants only. In contrast, the addition of HBIG in infants of HBsAg(&#x02009;+) mothers with/without the expansion of TDF prophylaxis to HBeAg(&#x02009;+) mothers was very cost-effective or even dominant to the current practice. The results from this study could provide very useful evidence to support policy decision making in Vietnam, as well as other LMIC or LIC with similar context, especially in countries with high prevalence of HBsAg and aiming towards HBV elimination.</p></sec><sec id="Sec21" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12913_2024_12152_MOESM1_ESM.docx"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12913_2024_12152_MOESM2_ESM.docx"><caption><p>Supplementary Material 2.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>MTCT</term><def><p id="Par2">Mother-to-child transmission</p></def></def-item><def-item><term>HBB</term><def><p id="Par3">Hepatitis B virus</p></def></def-item><def-item><term>HBIG</term><def><p id="Par4">Hepatitis B immunoglobulin</p></def></def-item><def-item><term>TDF</term><def><p id="Par5">Tenofovir disoproxil fumarate</p></def></def-item><def-item><term>VL</term><def><p id="Par6">Viral load</p></def></def-item><def-item><term>WHO</term><def><p id="Par7">World Health Organization</p></def></def-item><def-item><term>BD</term><def><p id="Par8">Birth dose</p></def></def-item><def-item><term>NEPI</term><def><p id="Par9">National Expand Program on Immunization</p></def></def-item><def-item><term>UMIC</term><def><p id="Par10">Upper-middle-income country</p></def></def-item><def-item><term>LMIC</term><def><p id="Par11">Lower-middle-income country</p></def></def-item><def-item><term>LBIT</term><def><p id="Par12">Laboratory based immunoassay test</p></def></def-item><def-item><term>CHB</term><def><p id="Par13">Chronic hepatitis B</p></def></def-item><def-item><term>CC</term><def><p id="Par14">Compensated cirrhosis</p></def></def-item><def-item><term>DCC</term><def><p id="Par15">Decompensated cirrhosis</p></def></def-item><def-item><term>HCC</term><def><p id="Par16">Hepatocellular carcinoma</p></def></def-item><def-item><term>RDT</term><def><p id="Par17">Rapid diagnostic test</p></def></def-item><def-item><term>RCT</term><def><p id="Par18">Randomized controlled trials</p></def></def-item><def-item><term>DMC</term><def><p id="Par19">Direct medical cost</p></def></def-item><def-item><term>EE</term><def><p id="Par20">Economic evaluation</p></def></def-item><def-item><term>WTP</term><def><p id="Par21">Willingness-to-pay</p></def></def-item><def-item><term>INMB</term><def><p id="Par22">Incremental net monetary benefits</p></def></def-item><def-item><term>QALY</term><def><p id="Par23">Quality adjusted life years</p></def></def-item><def-item><term>SE</term><def><p id="Par24">Standard error</p></def></def-item><def-item><term>CI</term><def><p id="Par25">Confidence interval</p></def></def-item><def-item><term>PSA</term><def><p id="Par26">Probabilistic sensitivity analysis</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank Van T.B Ngo, Diu T. Pham, Tuan M. Tran, Thao T.P. Nguyen and Khoa D.
</p></ack><notes notes-type="author-contribution"><title>Authors' contributions</title><p>H.T.N, U.C., M.V.H, M.T., and A.T. designed the study, H.T.N, V.Q.T., and Q.D.T. collected data, H.T.N, U.C., M.V.H, M.T., A.T., and N.P analyzed and interpreted the results, U.C., M.V.H, M.T., A.T., and N.P validated the results. All authors drafted and reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Mahidol University. This study was supported by Mahidol University and the International Decision Support Initiative (iDSI) through a grant awarded to UC (OPP1087363). This work was produced as part of the International Decision Support Initiative, which supports countries to get the best value for money from health spending. iDSI receives funding support from the Bill &#x00026; Melinda Gates Foundation, the UK Department for International Development, and the Rockefeller Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in this published article and its supplementary information files.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par57">The study was approved by the Institutional Review Board of School of Medicine, Vietnam National University Ho Chi Minh City (02/Q&#x00110;-IRB-VN01.017) and the Faculty of Dentistry and Faculty of Pharmacy, Mahidol University, Institutional Review Board (No.78.0319/EC.618). The need for informed consent for this study was waived by the ethics committees, as all data were obtained from published studies. All procedures performed in the study were in compliance with international guidelines for human research protection such as Declaration of Helsinki, the Belmont Report.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par58">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par59">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organization. Hepatitis B, &#x0003c;<ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-b">https://www.who.int/news-room/fact-sheets/detail/hepatitis-b</ext-link>&#x0003e; .2022.</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Navabakhsh</surname><given-names>B</given-names></name><name><surname>Mehrabi</surname><given-names>N</given-names></name><name><surname>Estakhri</surname><given-names>A</given-names></name><name><surname>Mohamadnejad</surname><given-names>M</given-names></name><name><surname>Poustchi</surname><given-names>H</given-names></name></person-group><article-title>Hepatitis B Virus Infection during Pregnancy: Transmission and Prevention</article-title><source>Middle East J Dig Dis</source><year>2011</year><volume>3</volume><fpage>92</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">25197539</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Navabakhsh B, Mehrabi N, Estakhri A, Mohamadnejad M, Poustchi H. Hepatitis B Virus Infection during Pregnancy: Transmission and Prevention. Middle East J Dig Dis. 2011;3:92&#x02013;102.<pub-id pub-id-type="pmid">25197539</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>NP</given-names></name><name><surname>Jamieson</surname><given-names>DJ</given-names></name><name><surname>Murphy</surname><given-names>TV</given-names></name></person-group><article-title>Prevention of Perinatal Hepatitis B Virus Transmission</article-title><source>J Pediatric Infect Dis Soc.</source><year>2014</year><volume>3</volume><issue>Suppl 1</issue><fpage>S7</fpage><lpage>S12</lpage><pub-id pub-id-type="doi">10.1093/jpids/piu064</pub-id><pub-id pub-id-type="pmid">25232477</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Nelson NP, Jamieson DJ, Murphy TV. Prevention of Perinatal Hepatitis B Virus Transmission. J Pediatric Infect Dis Soc. 2014;3(Suppl 1):S7&#x02013;12. 10.1093/jpids/piu064.<pub-id pub-id-type="pmid">25232477</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Hyams</surname><given-names>KC</given-names></name></person-group><article-title>Risks of chronicity following acute hepatitis B virus infection: A review</article-title><source>Clin Infect Dis.</source><year>1995</year><volume>20</volume><fpage>992</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1093/clinids/20.4.992</pub-id><pub-id pub-id-type="pmid">7795104</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Hyams KC. Risks of chronicity following acute hepatitis B virus infection: A review. Clin Infect Dis. 1995;20:992&#x02013;1000. 10.1093/clinids/20.4.992.<pub-id pub-id-type="pmid">7795104</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">World Health Organization. Global health sector strategy on viral hepatitis 2016&#x02013;2021: Towards ending viral hepatitis. Geneva: World Health Organization. 2016:22&#x02013;37. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/WHO-HIV-2016.06">https://www.who.int/publications/i/item/WHO-HIV-2016.06</ext-link>.</mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>HT</given-names></name><etal/></person-group><source>Am J Obstet Gynecol.</source><year>2022</year><volume>227</volume><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.ajog.2022.02.042</pub-id><pub-id pub-id-type="pmid">35263648</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Nguyen HT, et al. Am J Obstet Gynecol. 2022;227:163&#x02013;72. 10.1016/j.ajog.2022.02.042.<pub-id pub-id-type="pmid">35263648</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>F</given-names></name><etal/></person-group><article-title>Efficacy of oral antiviral drugs to prevent mother-to-child transmission of hepatitis B virus: a network meta-analysis</article-title><source>Hepatol Int.</source><year>2020</year><volume>14</volume><fpage>338</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1007/s12072-020-10024-2</pub-id><pub-id pub-id-type="pmid">32130674</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Jia F, et al. Efficacy of oral antiviral drugs to prevent mother-to-child transmission of hepatitis B virus: a network meta-analysis. Hepatol Int. 2020;14:338&#x02013;46. 10.1007/s12072-020-10024-2.<pub-id pub-id-type="pmid">32130674</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z-X</given-names></name><etal/></person-group><article-title>Comparative Effectiveness of Prophylactic Strategies for Perinatal Transmission of Hepatitis B Virus: A Network Meta-analysis of Randomized Controlled Trials</article-title><source>Open Forum Infect Dis.</source><year>2017</year><volume>4</volume><fpage>ofx225</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofx225</pub-id><pub-id pub-id-type="pmid">29181424</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Chen Z-X, et al. Comparative Effectiveness of Prophylactic Strategies for Perinatal Transmission of Hepatitis B Virus: A Network Meta-analysis of Randomized Controlled Trials. Open Forum Infect Dis. 2017;4:ofx225. 10.1093/ofid/ofx225.<pub-id pub-id-type="pmid">29181424</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis</article-title><source>Hepatol Int.</source><year>2020</year><volume>14</volume><fpage>180</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1007/s12072-020-10026-0</pub-id><pub-id pub-id-type="pmid">32193814</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Wu Y, et al. Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis. Hepatol Int. 2020;14:180&#x02013;9. 10.1007/s12072-020-10026-0.<pub-id pub-id-type="pmid">32193814</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab></person-group><article-title>EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection</article-title><source>J Hepatol.</source><year>2017</year><volume>67</volume><fpage>370</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2017.03.021</pub-id><pub-id pub-id-type="pmid">28427875</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370&#x02013;98. 10.1016/j.jhep.2017.03.021.<pub-id pub-id-type="pmid">28427875</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Sarin</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update</article-title><source>Hepatol Int.</source><year>2016</year><volume>10</volume><fpage>1</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1007/s12072-015-9675-4</pub-id><pub-id pub-id-type="pmid">26563120</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Sarin SK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol Int. 2016;10:1&#x02013;98. 10.1007/s12072-015-9675-4.<pub-id pub-id-type="pmid">26563120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Terrault</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance</article-title><source>Clin Liver Dis.</source><year>2018</year><volume>12</volume><fpage>33</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1002/cld.728</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Terrault NA, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Clin Liver Dis. 2018;12:33&#x02013;4. 10.1002/cld.728.</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: Guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization. 2020:11&#x02013;20. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789240002708">https://www.who.int/publications/i/item/9789240002708</ext-link>.</mixed-citation></ref><ref id="CR14"><label>14</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Flower</surname><given-names>B</given-names></name><etal/></person-group><article-title>Seroprevalence of Hepatitis B, C and D in Vietnam: A systematic review and meta-analysis</article-title><source>Lancet Reg Health West Pac.</source><year>2022</year><volume>24</volume><fpage>100468</fpage><pub-id pub-id-type="doi">10.1016/j.lanwpc.2022.100468</pub-id><pub-id pub-id-type="pmid">35573318</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Flower B, et al. Seroprevalence of Hepatitis B, C and D in Vietnam: A systematic review and meta-analysis. Lancet Reg Health West Pac. 2022;24:100468. 10.1016/j.lanwpc.2022.100468.<pub-id pub-id-type="pmid">35573318</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Ministry of Health. 3310/Q&#x00110;-BYT. Guidelines for diagnosing and treating of hepatitis B. Ministry of Health. 2019.</mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Drug Administration of Vietnam. Bidding results, &#x0003c;<ext-link ext-link-type="uri" xlink:href="https://dav.gov.vn/thong-tin-dau-thau-thuoc-cn8-page3.html">https://dav.gov.vn/thong-tin-dau-thau-thuoc-cn8-page3.html</ext-link>&#x0003e; .2022.</mixed-citation></ref><ref id="CR17"><label>17</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>VTT</given-names></name><etal/></person-group><article-title>Feasibility, benefits, and cost-effectiveness of adding universal hepatitis B and syphilis testing to routine antenatal care services in Thai Nguyen province</article-title><source>Vietnam. Int J STD AIDS.</source><year>2021</year><volume>32</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1177/0956462420953722</pub-id><pub-id pub-id-type="pmid">33349143</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Nguyen VTT, et al. Feasibility, benefits, and cost-effectiveness of adding universal hepatitis B and syphilis testing to routine antenatal care services in Thai Nguyen province. Vietnam Int J STD AIDS. 2021;32:135&#x02013;43. 10.1177/0956462420953722.<pub-id pub-id-type="pmid">33349143</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Ha, N.T. Economic evaluation of prophylaxis strategies to prevent mother-to-child transmission of hepatitis B virus infection in Vietnam. Doctoral thesis, Mahidol University; 2023.</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">World Health Organization. Guidelines on hepatitis B and C testing; 2017:30&#x02013;59. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789241549981">https://www.who.int/publications/i/item/9789241549981</ext-link>.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">World Health Organization. Guidelines for the prevention, diagnosis, care and treatment of people with chronic hepatitis B infection, &#x0003c;<ext-link ext-link-type="uri" xlink:href="https://iris.who.int/bitstream/handle/10665/376353/9789240090903-eng.pdf">https://iris.who.int/bitstream/handle/10665/376353/9789240090903-eng.pdf</ext-link>&#x0003e; .2024.</mixed-citation></ref><ref id="CR21"><label>21</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Amini</surname><given-names>A</given-names></name><etal/></person-group><article-title>Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis</article-title><source>BMC Infect Dis.</source><year>2017</year><volume>17</volume><fpage>698</fpage><pub-id pub-id-type="doi">10.1186/s12879-017-2772-3</pub-id><pub-id pub-id-type="pmid">29143619</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Amini A, et al. Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis. BMC Infect Dis. 2017;17:698. 10.1186/s12879-017-2772-3.<pub-id pub-id-type="pmid">29143619</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">World Health Organization. Life tables: Life tables by country Vietnam, &#x0003c;<ext-link ext-link-type="uri" xlink:href="https://apps.who.int/gho/data/view.searo.61830?lang=en">https://apps.who.int/gho/data/view.searo.61830?lang=en</ext-link>&#x0003e; .2019.</mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Miyakawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hepatitis B virus infection among pregnant mothers and children after the introduction of the universal vaccination program in Central Vietnam</article-title><source>Sci Rep.</source><year>2021</year><volume>11</volume><fpage>8676</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-87860-1</pub-id><pub-id pub-id-type="pmid">33883610</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Miyakawa M, et al. Hepatitis B virus infection among pregnant mothers and children after the introduction of the universal vaccination program in Central Vietnam. Sci Rep. 2021;11:8676. 10.1038/s41598-021-87860-1.<pub-id pub-id-type="pmid">33883610</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Due</surname><given-names>OT</given-names></name><etal/></person-group><article-title>Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam</article-title><source>Value Health.</source><year>2020</year><volume>23</volume><fpage>1180</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2020.03.018</pub-id><pub-id pub-id-type="pmid">32940236</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Due OT, et al. Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam. Value Health. 2020;23:1180&#x02013;90. 10.1016/j.jval.2020.03.018.<pub-id pub-id-type="pmid">32940236</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Toi</surname><given-names>PL</given-names></name><etal/></person-group><article-title>Economic evaluation of population-based type 2 diabetes mellitus screening at different healthcare settings in Vietnam</article-title><source>PLoS One.</source><year>2021</year><volume>16</volume><fpage>e0261231</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0261231</pub-id><pub-id pub-id-type="pmid">34941883</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Toi PL, et al. Economic evaluation of population-based type 2 diabetes mellitus screening at different healthcare settings in Vietnam. PLoS One. 2021;16:e0261231. 10.1371/journal.pone.0261231.<pub-id pub-id-type="pmid">34941883</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">General Statistics Office. Monthly consumer price index, &#x0003c;<ext-link ext-link-type="uri" xlink:href="https://www.gso.gov.vn/en/px-web/?pxid=E0834&#x00026;theme=Trade%2C%20Price%20and%20Tourist">https://www.gso.gov.vn/en/px-web/?pxid=E0834&#x00026;theme=Trade%2C%20Price%20and%20Tourist</ext-link>&#x0003e; .2023.</mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>YX</given-names></name><etal/></person-group><article-title>Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B</article-title><source>Qual Life Res.</source><year>2014</year><volume>23</volume><fpage>2355</fpage><lpage>2363</lpage><pub-id pub-id-type="doi">10.1007/s11136-014-0670-3</pub-id><pub-id pub-id-type="pmid">24627090</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Jia YX, et al. Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Qual Life Res. 2014;23:2355&#x02013;63. 10.1007/s11136-014-0670-3.<pub-id pub-id-type="pmid">24627090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Thavorncharoensap</surname><given-names>M</given-names></name><etal/></person-group><article-title>Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?</article-title><source>Clinicoecon Outcomes Res.</source><year>2023</year><volume>5</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.2147/ceor.S38062</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Thavorncharoensap M, et al. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res. 2023;5:29&#x02013;36. 10.2147/ceor.S38062.</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Ministry of Health. No. 7130/QD-BYT. National action plan towards the elimination of hepatitis B transmitted from mother-to-child from 2018 &#x02013; 2023. Ministry of Health; 2018.</mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Bierhoff</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tenofovir disoproxil fumarate in pregnancy for prevention of mother to child transmission of hepatitis B in a rural setting on the Thailand-Myanmar border: a cost-effectiveness analysis</article-title><source>BMC Pregnancy Childbirth.</source><year>2021</year><volume>21</volume><fpage>157</fpage><pub-id pub-id-type="doi">10.1186/s12884-021-03612-z</pub-id><pub-id pub-id-type="pmid">33618698</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Bierhoff M, et al. Tenofovir disoproxil fumarate in pregnancy for prevention of mother to child transmission of hepatitis B in a rural setting on the Thailand-Myanmar border: a cost-effectiveness analysis. BMC Pregnancy Childbirth. 2021;21:157. 10.1186/s12884-021-03612-z.<pub-id pub-id-type="pmid">33618698</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Owusu-Edusei</surname><given-names>K</given-names><suffix>Jr</suffix></name><name><surname>Schillie</surname><given-names>SF</given-names></name><name><surname>Murphy</surname><given-names>TV</given-names></name></person-group><article-title>Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load</article-title><source>Obstet Gynecol.</source><year>2014</year><volume>123</volume><fpage>929</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1097/aog.0000000000000124</pub-id><pub-id pub-id-type="pmid">24785842</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load. Obstet Gynecol. 2014;123:929&#x02013;37. 10.1097/aog.0000000000000124.<pub-id pub-id-type="pmid">24785842</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Owusu-Edusei</surname><given-names>K</given-names><suffix>Jr</suffix></name><name><surname>Schillie</surname><given-names>SF</given-names></name><name><surname>Murphy</surname><given-names>TV</given-names></name></person-group><article-title>Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection</article-title><source>Hepatology.</source><year>2016</year><volume>63</volume><fpage>1471</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1002/hep.28310</pub-id><pub-id pub-id-type="pmid">26509655</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection. Hepatology. 2016;63:1471&#x02013;80. 10.1002/hep.28310.<pub-id pub-id-type="pmid">26509655</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>HF</given-names></name><name><surname>Chen</surname><given-names>HH</given-names></name></person-group><article-title>Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection</article-title><source>Pharmacoeconomics.</source><year>2011</year><volume>29</volume><fpage>1063</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.2165/11586470-000000000-00000</pub-id><pub-id pub-id-type="pmid">22077578</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Hung HF, Chen HH. Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection. Pharmacoeconomics. 2011;29:1063&#x02013;73. 10.2165/11586470-000000000-00000.<pub-id pub-id-type="pmid">22077578</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Shin</surname><given-names>HY</given-names></name><name><surname>Park</surname><given-names>SM</given-names></name></person-group><article-title>Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea</article-title><source>Cost Eff Resour Alloc.</source><year>2018</year><volume>16</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/s12962-018-0088-9</pub-id><pub-id pub-id-type="pmid">29467596</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Lee D, Shin HY, Park SM. Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea. Cost Eff Resour Alloc. 2018;16:6. 10.1186/s12962-018-0088-9.<pub-id pub-id-type="pmid">29467596</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Rumgay</surname><given-names>H</given-names></name><etal/></person-group><article-title>Global, regional and national burden of primary liver cancer by subtype</article-title><source>Eur J Cancer</source><year>2022</year><volume>161</volume><fpage>108</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2021.11.023</pub-id><pub-id pub-id-type="pmid">34942552</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Rumgay H, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108&#x02013;18.<pub-id pub-id-type="pmid">34942552</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>F</given-names></name><name><surname>Woodring</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name></person-group><article-title>Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China</article-title><source>Int. J. Epidemiol.</source><year>2018</year><volume>47</volume><fpage>1529</fpage><lpage>1537</lpage><pub-id pub-id-type="doi">10.1093/ije/dyy077</pub-id><pub-id pub-id-type="pmid">29757383</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Cui F, Woodring J, Chan P, Xu F. Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China. Int J Epidemiol. 2018;47:1529&#x02013;37. 10.1093/ije/dyy077.<pub-id pub-id-type="pmid">29757383</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>TamandjouTchuem</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis</article-title><source>Vaccine.</source><year>2021</year><volume>39</volume><fpage>3141</fpage><lpage>3151</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.04.041</pub-id><pub-id pub-id-type="pmid">33962836</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">TamandjouTchuem CR, et al. Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis. Vaccine. 2021;39:3141&#x02013;51. 10.1016/j.vaccine.2021.04.041.<pub-id pub-id-type="pmid">33962836</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">World Health Organization. Triple elimination initiative of mother-to-child transmission of HIV, syphilis and hepatitis B, &#x0003c;<ext-link ext-link-type="uri" xlink:href="https://www.who.int/initiatives/triple-elimination-initiative-of-mother-to-child-transmission-of-hiv-syphilis-and-hepatitis-b">https://www.who.int/initiatives/triple-elimination-initiative-of-mother-to-child-transmission-of-hiv-syphilis-and-hepatitis-b</ext-link>&#x0003e; .2023.</mixed-citation></ref></ref-list></back></article>